This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Merrimack Pharmaceuticals' Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors





CAMBRIDGE, Mass., June 4, 2013 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced results from a Phase 1 clinical study that indicate the novel antibody MM-121 can be combined with standard doses of certain cytotoxic agents  for investigation as treatment for patients with advanced solid tumors. The research was presented at the 2013 American Society of Clinical Oncology Annual Meeting in Chicago, IL, May 31June 4, 2013.

The Phase 1 study of 43 patients with advanced solid tumors established that MM-121 can be combined at its recommended single agent dose with gemcitabine, pemetrexed, cabazitaxel or carboplatin.

MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in tumor growth and survival across multiple malignancies. Preclinical research in several model systems has shown that by inhibiting ErbB3 signaling, MM-121 may restore sensitivity, delay resistance and enhance the effect of certain cytotoxic agents as a combination therapy.

"These data serve as the foundation for moving MM-121 into potential Phase 2 studies in combination with these chemotherapy agents in certain tumor types," said Akos Czibere, MD, Ph.D., Senior Medical Director of the MM-121 program at Merrimack. "MM-121 has the potential to complement the impact of several existing standard-of-care therapies and we look forward to further exploring its promise."

Sanofi and Merrimack entered into an exclusive, global license and collaboration agreement for MM-121 in 2009.

Study Methodology & Results



Abstract Number: 2609 Abstract Title: A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced solid tumors. Session Title: General Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics Presenter: Monica Arnedos, MD, Institut Gustave Roussy, Paris, France

In studying the safety of MM-121 in combination with gemcitabine (Arm A), carboplatin (Arm B),  pemetrexed (Arm C) and cabazitaxel (Arm D) for subjects with advanced cancer, patients were treated in a dose escalation "3+3" design. MM-121 was administered weekly in combination with these cytotoxic agents to assess the safety, tolerability and pharmacokinetics of the antibody. Doses were escalated until the maximum tolerated dose (MTD) was identified and/or the combination was shown to be tolerable at the highest planned doses. Secondary objectives included determining the objective response rate, clinical benefit rate, pharmacokinetics and immunogenicity of MM-121. No MTD was identified for the combination of MM-121 and standard doses of gemcitabine, pemetrexed and cabazitaxel; a MTD of carboplatin (AUC 5) was identified in combination with the recommended dose of MM-121 (40 mg/kg loading, followed by 20 mg/kg weekly maintenance). The two dose limiting toxicities observed in combination with carboplatin were one grade 3-4 prolonged thrombocytopenia and one grade 3 maculopapular rash.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs